Прилепская В.Н., Межевитинова Е.А. с соавт. Гормональная контрацепция, 2011.

Прилепская В.Н. Лечебные возможности гормональной контрацепции. Русский медицинский журнал, 1999; 1, 2: 1-5.

Информационное письмо для практических врачей АГЭ 2011 г.

Gupta SK, Gupta N, Suman P et al. Zonapellucida-based contraceptive vaccines for human and animal utility. J Reprodlmmunol. 2011 Mar: 88(2): 240-246.

The safety and contraceptive efficacy of a 24-day low-dose oral contraceptive regimen containing gestodene 60 microg and ethinylestra-diol 15 microg. Eur J Contracept Reprod Health Care 1999; 4(Suppl. 2): 9-15.

Ahrendt HJ, Nisand I, Bastianelli C et al. Efficacy, acceptability and tolerability of the combined contraceptive ring, NuvaRing, compared with an oral contraceptive containing 30 microg of ethinyl estradiol and 3 mg of drospirenone. Contraception 2006; 74(6): 451-457.

Palacios S, Wildt L, Parke S et al. Efficacy and safety of a novel oral contraceptive based on oestradiol (oestradiol valerate/dienogest): a Phase III trial. Eur J Obstet Gynecol Reprod Biol 2010; 149: 57-62.

Archer DF, Lasa IL. Tailoring combination oral contraceptives to the individual woman. J Womens Health (Larchmt). 2011 Jun; 20 (6): 879-891.

David PS, Boatwright EA, Tozer BS, Verma DP, Blair JE, Mayer AP et al. Hormonal contraception update. Mayo Clin Proc 2006; 81: 949-954.

World Health Organization. Medical eligibility criteria for contraceptive use. 3rd ed. Geneva: World Health Organization; 2004.

Nahum GG, Parke S, Efficacy and tolerability of a new oral contraceptivecontaining estradiol and dienogest ObstetGynecol 2008; 111(4 Suppl.).